Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced that the Company will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020 at 3:00 p.m. ET.
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020 at 3:00 p.m. ET.
A live webcast of the presentation can be accessed on the investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage’s website following the conference.
About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200601005011/en/
Investors
Jeff Boyle
347-247-5089
jeff.boyle@sagerx.com
Media
Maureen L. Suda
617-949-4289
maureen.suda@sagerx.com
Source: Sage Therapeutics, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20200601005011/en